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Hypothyroidism induces several metabolic changes that allow understanding some physiopathological mechanisms. Under
experimental hypothyroid conditions in rats, heart and kidney are protected against oxidative damage induced by ischemia
reperfusion. An increased resistance to opening of the permeability transition pore seems to be at the basis of such protection.
Moreover,glomerularﬁltrationrateofhypothyroidkidneyislowasaresultofadenosinereceptors-inducedrenalvasoconstriction.
The vascular tone of aorta is also regulated by adenosine in hypothyroid conditions. In other context, thyroid hormones regulate
lipoprotein metabolism. High plasma level of LDL cholesterol is a common feature in hypothyroidism, due to a low expression of
the hepatic LDL receptor. In contrast, HDL-cholesterol plasma levels are variable in hypothyroidism; several proteins involved in
HDL metabolism and structure are expressed at lower levels in experimental hypothyroidism. Based on the positive inﬂuence of
thyroid hormones on lipoprotein metabolism, thyromimetic drugs are promising for the treatment of dyslipidemias. In summary,
hypothyroid status has been useful to understand molecular mechanisms involved in ischemia reperfusion, regulation of vascular
function and intravascular metabolism of lipoproteins.
1.Introduction
The inﬂuence of thyroid hormones on metabolic processes
has been widely recognized, particularly the profound
changes in ATP metabolism. ATP production is primarily
driven by mitochondrion, along with other relevant pro-
cesses, including intracellular Ca2+ regulation, redox signal-
ing, and apoptosis triggering [1]. In this respect, it is known
that hypothyroidism diminishes oxygen consumption and
promotes low metabolism that lead to disturbances in
hemodynamic,cardiac,andrenalfunctions,aswellasinlipid
metabolism.
Adenosine is a vasoactive compound that may induce
dysfunction of several physiological mechanisms. In this
regard, little attention has been given to the relationship
between the eﬀects of the nucleoside adenosine, a metabolite
ofATP,andthethyroidstatus,speciﬁcallyinhypothyroidism.
Lipoproteins proﬁle is another aspect aﬀected in hypothyroi-
dism; increased low-density lipoproteins- (LDL-) cholesterol
plasma levels is the most common feature. The metabolism
of high-density lipoproteins (HDLs) is also deeply impaired;
severalgenescodingforproteinsinvolvedintheintravascular
metabolism of HDL are regulated by thyroid hormones.
However, the altered HDL metabolism has not been consid-
ered in its real dimension because HDL-cholesterol plasma
levels vary widely among diﬀerent studies in patients or
animal models of hypothyroidism.
In this paper, we will focus on hypothyroidism as model
to understand new physiological mechanisms that inﬂuence
themitochondrion,thecardiovascularsystem,theregulation
of vascular tone, the kidney, and lipid metabolism.
2.HypothyroidismandMitochondria
Thyroid hormones regulate the expression of several
membrane-associated respiratory enzymes and metabolite
carriers in mitochondria; whether the eﬀect of such regula-
tion is deleterious or beneﬁcial remains controversial [1–5].2 Journal of Thyroid Research
In hypothyroidism, it is known that the electron trans-
port chain complexes and the F1-Fo ATPase decrease their
activity in many tissues [6, 7]. Also cardiolipin, a dimeric
phospholipid synthesized by the mitochondrial enzyme car-
diolipin synthase, is activated by the thyroid hormones [8].
As a consequence, lower mitochondrial content of this phos-
pholipid has been reported in hypothyroidism, contributing
to the constellation of intracellular abnormalities in this
physiopathological situation [9, 10]. The function of several
mitochondrial proteins seems to be related to cardiolipin
content. Paradies et al. [11] showed that the activity of
cytochrome c oxidase was diminished in mitochondria iso-
lated from hypothyroid rats, and that its normal activity was
recovered after the addition of cardiolipin. Other mitochon-
drialproteinaﬀectedbythehypothyroidstatusistheadenine
nucleotide translocase (ANT). Normal ADP/ATP exchange
activity of ANT depends on cardiolipin [12]; Paradies
et al. [11] demonstrated that cardiolipin content in liver
mitochondria from hypothyroid rats was 24nmol/mg versus
40nmol/mg in euthyroid rats. These values correlated with a
diminution in ANT levels, from 58nmol/mg in control rats
to 40nmol/mg in hypothyroid rats. In addition to its normal
function, ANT forms the inner membrane channel of the
mitochondrial permeability transition pore (MPTP)[13–15]
which allows the movement of matrix ions and metabolites
through the mitochondrial membrane (Figure 1). Binding of
cyclophilin-D (CyP-D) to ANT matrix surface facilitates a
calcium-triggered conformational change converting it from
a speciﬁc transporter to a nonspeciﬁc pore. Both proteins
along with the voltage-dependent anion channel (VDAC)
and cardiolipin probably represent the minimum MPTP
conﬁguration [13–15]. Once integrated, MPTP opening is
favored by Ca2+ accumulation in the matrix or by inhibiting
the ADP/ATP translocase activity with the speciﬁc inhibitor
carboxyatractyloside (CAT) [16]. As mentioned above, the
translocase activity in the membrane depends on the lipid
constitution of the bilayer, in other words, on the cardiolipin
content [17, 18]. Since mitochondria from hypothyroid
rats are characterized by low cardiolipin content and by
low expression of ANT [11], MPTP formation in these
mitochondriaisimpaired[17].Experimentscarriedoutwith
mitochondria from thyroidectomized rats, whose blood T4
levels diminished from 6.42 ± 0.024 to 1.49 ± 0.12μg/dL
after surgery, showed that the transition pore remained
closed, regardless of the Ca2+ overload [17].
A controversial issue in hypothyroidism is the apparent
protection against tissue injury derived from ischemia reper-
fusion [18–20]. Tissue injury by reperfusion is an important
complication involved in organ transplantation; in kidney
transplantation, a delay in graft function has been attributed
to the deleterious eﬀect of excessive release of reactive
oxygenspecies(ROS)[21].TheincreasedproductionofROS
inducesaleakageofmitochondria matrixcomponents,likely
as a consequence of membrane protein and lipid peroxida-
tion [22]. Mitochondrial membrane increased permeability
leads to massive Ca2+ loss; in mitochondria isolated from
euthyroid-rat kidneys subjected to ischemia/reperfusion, the
initial Ca2+ accumulation inside mitochondria was followed
almost immediately by a slow release of the cation. In
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Figure 1: Conversion of the adenine nucleotide translocase (ANT)
to permeability transition pore. (a) Under euthyroid conditions,
ANT allows the selective exchange (dotted lines) of ADP and ATP
betweenthecitosolandthemitochondrionmatrix.Ca2+ triggersthe
assembling of ANT with cardiolipin and other proteins (not shown
in the ﬁgure) to integrate the permeability transition pore. (b) In
hypothyroidism, the low content of cardiolipin in the mitochon-
drion membrane limits the pore formation, thus conserving the
ANT function and matrix content unaltered. See the text for details.
contrast, mitochondria isolated from ischemic/reperfused
kidney of hypothyroid rats were capable of maintaining the
accumulated Ca2+.
Oxidative stress induces opening of the pore, which
allows depletion of several compounds from the mito-
chondrial matrix including NAD+ and cytochrome c [19,
23]. In this context, NAD+ and cytochrome c content
in kidney mitochondria also depend on thyroid status.
Matrix NAD+ fell down to about 10% of control lev-
els in mitochondria isolated from euthyroid rats after
ischemia/reperfusion. In contrast, matrix NAD+ increased
around 40% in mitochondria isolated from hypothyroid rats
subjected to ischemia/reperfusion with respect to control
mitochondria. As previously reported, the MPTP lies under
the progression of the apoptotic mitochondrial pathway,
providing mitochondrial cytochrome c release [19, 23].
Mitochondria isolated from ischemic/reperfused euthyroid
kidney showed lower levels of cytochrome c, as compared
with mitochondria isolated from reperfused kidney from
hypothyroid rats (40% versus 10%) [19].
Hypothyroidism protection, against nonspeciﬁc mem-
brane leakage, has also been shown by using inhibitors
of the electron transport and oxidative phosphorylation
uncouplers [19, 20].Journal of Thyroid Research 3
Based on the aforementioned evidence, we can suggest
that the thyroid status inﬂuences mitochondrial membrane
permeability, that is, hypothyroidism renders mitochondria
membrane less prone to leak calcium. In support of the
evidence mentioned above, it is important to mention
that mitochondria isolated from hyperthyroid rats have an
increased nonspeciﬁc permeability, since they undergo per-
meability transition in the absence of inducing agents [24].
The resistance to increased permeability in mitochondria
from hypothyroid rats should be due to the inability of ANT
to convert itself into a nonspeciﬁc pore. Such a failure must
be attributed to the low content of cardiolipin, which is part
of the annulus of the carrier [12, 15] and is indispensable
for its adequate function. Furthermore, it has been proposed
that cardiolipin would be the target site for Ca2+ to induce
pore opening (Figure 1). Therefore, in mitochondria with
low content of cardiolipin, Ca2+ fails to induce membrane
leakage. It should be noted that cardiolipin content in kidney
mitochondria from hypothyroid rats was about 60% of those
isolated from control rats [25].
Thyroid hormones aﬀect other mitochondrial functions
that are mediated by mechanisms diﬀerent to the cardiolipin
membrane content; hypothyroidism aﬀects the expression
of mitochondrial proteins from the respiratory chain. In
this regard, it has been shown that Coenzyme Q10 levels
decreased, as well as the antioxidant capacity of mitochon-
dria [26, 27]. Of particular interest, T3 regulates the energy
dissipation related to proton leakage. Basal mitochondrial
proton leakage accounts for about 25% of whole-body
resting energy expenditure; therefore, the modulation of
proton leakage by T3 may result in signiﬁcant control of
total body energy expenditure. In this context, the authors in
[28] have shown that mitochondrial PTP gating could not be
ascribedtoT3-inducedchangesinthemitochondrialcontent
of integral PTP components, that is, ANT, cyclophilin D,
or VDAC, despite T3-induced increases in the expression
of ANT and cyclophylin D. In vivo T3 treatment resulted
in pronounced increase in liver mitochondrial Bax together
with pronounced decrease in mitochondrial Bcl2, while
hypothyroidism resulted in opposite eﬀects that may be
reversed by T3 [29]; mitochondrial free Bax induced by T3
resultsinalow-conductancePTPgating[28],theconsequent
proton leakage, and ﬁnally energy expenditure. The compre-
hension of the T3 transduction pathway that is involved in
regulating mitochondrial energetics may oﬀer novel targets
for thyromimetics designed to modulate energy expenditure.
3. HypothyroidismandHeart
Reperfusion Damage
Heart reperfusion achieved through the implant of intra-
coronary stents or coronary by-passes in patients with
ischemic heart disease is an obligatory therapy to maintain
the myocardium viable after ischemia [30]. In this regard,
sudden reoxygenation occurring when the vessels are opened
causes considerable cell injury produced by the action
of oxygen-derived reactive species, generated mainly by
mitochondria [31, 32], associated to the Ca2+ overload
which contributes to the myocardial insult. Although the
controversial evidence of beneﬁcial or deleterious eﬀects of
hypothyroidism inheartreperfusionhasnotbeen completed
elucidated, several studies have shown an increased recovery
of cardiac function compared to the observed in normal
animals, as well as the protection against arrhythmias
[33].
Increasing evidence suggests that heart injury by reper-
fusion results from mitochondrial Ca2+ overload, oxidative
stress, adenine nucleotide depletion, elevated phosphate
concentration, and depolarization which in turn induces
the increase of nonspeciﬁc permeability [13]. As mentioned
above, mitochondria from hypothyroid rats are resistant
to permeability transition induced by Ca2+. In this sense,
myocardial tissue from hypothyroid rats is also resistant to
the damage exerted by reperfusion after an ischemic period
[34]. As shown in Figure 2(a) during the ischemic period,
hearts from control rats maintained sinusal rhythm; how-
ever, after removing the occlusion, reperfusion arrhythmias
were evident and continued during 10min, up to the end
of the experiment. Figure 2(b) shows ECG tracings from
hypothyroid rats, in which the cardiac frequency remained
unchanged during the ischemic period, as observed in
the control rats. Remarkably, when blood ﬂow was re-
established, no ventricular tachycardia was detected, and the
hearts remained in sinus rhythm along the experiment.
Figure 2 shows the electrocardiogram (ECG) tracing
from control and hypothyroid rats. Panel (a) illustrates the
electricproﬁleofacontrolrat,andPanel(b)ofahypothyroid
rat.
The mechanisms involved in the protection remain
under investigation, since they cannot been explained only
by the metabolic changes induced by hypothyroidism, that
is, low consumption of oxygen, higher myocardial glycogen
levels, and slow decline of ATP levels during ischemia.
Modiﬁcation of signal transduction molecules seems to
play an important role in the response to reperfusion of
hypothyroid hearts. PKCε is overexpressed, while phospho-
p46 and p54 JNK does not increase after I/R, suggesting
that they play an important role in the hypothyroidism-
induced cardioprotection [20]. In addition, a shift from
α to β myosin isoform expression and a lower expres-
sion of SERCA (sarco/endoplasmic reticulum Ca2+ ATPase)
occurred in hypothyroid hearts. Further experiments are
needed to completely understand the pathways involved in
the protective eﬀect of hypothyroidism in reperfusion.
4.InnovativeMechanismtoExplainAltered
Kidney Function inHypothyroidism
The renal alterations observed in hypothyroidism are well
known, among them: inability to produce maximally con-
centrated or diluted urine, reduced corticopapillary tissue
concentration gradients for urea, impaired urinary acidi-
ﬁcation, and decreased glomerular ﬁltration rate [35–37].
The abnormalities in glomerular hemodynamics at the
single nephron level are characterized by hypoperfusion
and decreased permeability of the glomerular capillaries,
resulting in a reduction of whole glomerular ﬁltration
rate [38]; these hemodynamic changes suggest the presence4 Journal of Thyroid Research
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Figure 2: Electrocardiogram of control (a) and hypothyroid (b) rats (modiﬁed from [34]). See text for explanation.
of vasoconstrictor compounds inﬂuencing renal function,
among them, participation of angiotensin II has been sug-
gested[39].However,thealterationsofATPmetabolismplay
a greater role in the physiopathological mechanisms involved
in the abnormalities of renal function in hypothyroidism.
In the presence of an abnormal nucleoside metabolism
characterized by a low production of ATP such as in
hypothyroidism, ATP degradation leads to a decreased
adenosine (ADO) production. To this regard, ADO has
been implicated in the regulation of glomerular ﬁltration
rate because of its unique vasoactive properties [40–42];
the nucleoside induces systemic vasodilation and renal
vasoconstriction. We demonstrated that administration of
an ADO receptors antagonist (PSPX) or administration of
exogenous ADO reverts the renal vasoconstriction of rats
with acute hypothyroidism (Figures 3 and 4) induced by
surgical thyroidectomy with parathyroid reimplant [38].
The observation that in hypothyroid rats the response in
renal hemodynamics to ADO administration is opposite to
the changes observed in sham-operated rats is remarkable;
these results suggest that ADO production is low and
stimulates preferentially ADO A1 receptors, which mediate
vasoconstriction.
Indeed, when a dose-response curve of single nephron
glomerular ﬁltration rate was obtained with intra-arterial
infusion of adenosine, the diﬀerence in the response between
sham-operated (Sham) and thyroidectomized (HTX) rats
was clearly demonstrated; single nephron glomerular rate
(SNGFR) decreased progressively with the various doses of
adenosine, as is well recognized [35–39]; in contrast, in the
HTX rats, there was an initial decrease of SNGFR, followed
by no changes and a marked increase with the highest dose
of adenosine, supporting the notion that ADO was low
in the kidney of HTX, and that increased concentrations
of adenosine were able to activate ADO A2 receptors that
induce vasodilation.
When ADO tissue content was measured in the kidneys
of Sham and HTX rats, the later had a very low content
of the nucleoside (Figure 5). These responses in glomerular
hemodynamics are in accordance with the fact that high
aﬃnity ADO A1 receptors are preferentially activated by low
concentrations of ADO, and the low aﬃnity ADO2 receptorsJournal of Thyroid Research 5
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Figure 3: Eﬀect of adenosine (ADO) on glomerular hemodynamics in normal and (NL) and hypothyroid (HTX) rats. (a) The balance
of glomerular blood ﬂow (GBF), the aﬀerent and eﬀerent resistances (AR, ER, resp.), and the permeability of the glomerular capillary
membrane (Kf) maintain a normal glomerular ﬁltration rate (GFR). (c) Administration of exogenous adenosine to normal rats produces
an increase in aﬀerent and eﬀerent resistances, which in turn result in decreased glomerular blood ﬂow and glomerular permeability;
as a ﬁnal consequence, the glomerular ﬁltration rate diminishes. (b) Glomerular hemodynamics of the hypothyroid kidney. There is a
glomerular vasoconstriction due to an increase in aﬀerent and eﬀerent resistances, a decrease in glomerular blood ﬂow, and permeability of
the glomerular capillary membrane, which results in a decreased glomerular ﬁltration rate. (d) When exogenous adenosine is administrated
to HTX rats, glomerular hemodynamics and GFR reach values near to normal. White arrows are indicative of magnitude of AR or ER,
whereas yellow arrows represent the magnitude of the glomerular ﬁltration rate.
are activated by high concentrations of the nucleoside
(Figure 5).
Hypothyroidism induces important changes in the en-
zymes involved in the metabolism of adenosine, and these
changes seem to be organ speciﬁc; thus, an increase in 5 
nucleotidase activity and a decrease in adenosine kinase
have been reported in brain tissue of hypothyroid rats
[43]. Moreover, 5 -nucleotidase and adenosine deaminase
activities in brown and white adipocytes have been shown to
decrease[44]associatedwithaloweradenosinecontent[45];
these cells develop an enhanced sensitivity to the nucleoside.
These ﬁndings are in agreement with the results obtained on
renalhemodynamicsinthekidneyofhypothyroidratsinour
study.
5. Participationof Adenosine Receptors
in the Regulation of RenalFunction in
Hypothyroidism
To further investigate the mechanisms of renal vasoconstric-
tion observed in hypothyroid rats, we performed binding
studies for A1 and A2 adenosine receptors in the kidneys
from hypothyroid rats [46]. We should point out that the
response of receptors to an agonist or antagonist depends
on both the number and aﬃnity of the receptors. We were
able to demonstrate two binding sites, a high (KH)a n da
low (KL)a ﬃnity for adenosine A1 and A2 receptors with
the radioligands (3H)CPA (ADO A1 agonist) and (3H)
CGS21680(ADOA2agonist)intherenalcortexandmedulla
of Sham and hypothyroid rats. In the renal cortex from
hypothyroid rats, no diﬀerences seem to exist in the high-
speciﬁcity state of the A1 receptor; however, signiﬁcant
lower values were observed in the low-speciﬁcity state for
aﬃnity and number of A1 receptors [46]. In contrast, at
the A2 receptors, an increase in aﬃnity and number of
the KH receptors was observed, with a decrease in aﬃnity
and number of the KL A2 receptors. These results are in
agreement with the cortical renal vasoconstriction observed
in hypothyroid rats, as well as the vasodilator response to
adenosine infusion [37].
The collecting ducts and loop of Henle of the jux-
tamedullary nephrons are located mainly in the outer strip
of the medulla. The ﬁne regulation of blood ﬂow and6 Journal of Thyroid Research
solute reabsorption occur in these structures [47], and the
medullary segments regulate the concentration of urine. A1
adenosine receptors are mainly in the low-aﬃnity state of the
outer and inner medulla in the hypothyroid kidney, but both
low and high aﬃnity A2 receptors increase and predominate
in the outer and inner medulla. In hypothyroidism, an
inability to achieve either maximal concentration or dilution
of urine is recognized [48–51]. A2 adenosine receptors have
been proposed to have a role in the regulation of the vasa
rectaandtransport mechanism in themedullarysegments of
the nephron [52]. Thus, the changes in A1 and A2 adenosine
receptors in the medullary segments may increase blood
ﬂow in the vessels, which results in a washout of interstitial
solutes, decreasing medullary tonicity, thereby producing
an impairment in the concentration of tubular ﬂuid and a
decrease in sodium and water reabsorption, [52–54]. Thus,
the changes in adenosine receptors in the renal medullary
segments from hypothyroid rats may contribute to induce
an inability to concentrate urine and a decrease in tubular
reabsorption, as observed in hypothyroidism.
6. Regulation of Renal Nitric Oxide Production
by AdenosineinHypothyroidism
It has been suggested that, in smooth muscle, the vasodila-
tion produced by adenosine may implicate nitric oxide pro-
duction (NO) [55]. In this regard, the vasodilator action of
ADO A2 analogs in coronary vasculature is mediated by NO
production, since A2 receptors are expressed in the endothe-
lial cells [56]. In isolated renal arteries, N6-cyclopentyl
adenosine (ADO A1 agonist) and 5 -N-ethylcarboxamido
adenosine (ADO A2 agonist) induce vasodilation by acti-
vation of ADO receptors located in the endothelium and
in smooth muscle, the latter involving NO release [56].
Furthermore, ADO stimulates NO production in endothelial
cell culture [57]. However, controversial evidence has been
obtained regarding the eﬀects of ADO on intact aortas and
aortic endothelium-denuded preparations contracted with
phenylephrine [58].
In the kidney, the release of NO increases, opposing the
vasoconstrictor eﬀects of ADO; the same mechanism occurs
with various vasoconstrictor substances such as angiotensin
II and norepinephrine [59]; however, interaction between
ADO and NO production has not been completely eluci-
dated. As mentioned above, in hypothyroidism, exogenous
adenosine vasodilates the kidney instead of exerting the
known vasoconstrictive eﬀect [38]. Thus, it is possible
that nitric oxide might be involved in this eﬀect. We have
demonstrated that whole glomerular ﬁltration rate (GFR)
decreased in response to exogenous ADO in Sham rats; in
contrast, in hypothyroid rats, the baseline of whole GFR was
signiﬁcantly lower than in the Sham group and increased
during administration of exogenous ADO. However, ADO
administration stimulated nitrite-nitrate (NO2
−/UNO3
−)
production in both normal (NL, or Sham) and HTX groups,
but this eﬀect was signiﬁcantly higher in the HTX rats (3.6
times increase in HTX versus 2.2 times increase in Sham). To
further study the eﬀects of ADO in the HTX kidney, ADO
A1 receptors were blocked with a speciﬁc receptor blocker
(DPSPX), which increased GFR in both groups; urinary
excretion of NO2
−/UNO3
− (UNO2
−/UNO3
−) increased in
NLandHTXgroups,butintheHTXrats,itreachedthesame
valuesasinShamrats.TheseresultssuggestaroleofADOA2
receptors in the increased GFR and UNO2
−/UNO3
− in NL
and HTX rats. Nevertheless, the dependency of GFR on NO
production seems to be very important in hypothyroidism.
To support the evidence that the increased UNO2
−/UNO3
−
induced by ADO and the ADO A1 blocker was actually due
to changes in NO production, NO synthase was inhibited
with L-NAME. L-NAME + ADO in NL rats decreased GFR
and prevented the increase in UNO2
−/UNO3
−; in HTX rats,
GFR as well as UNO2
−/UNO3
− remained unchanged, since
L-NAME completely prevented the renal vasodilator eﬀects
of ADO (Figure 6)[ 60].
As it can be observed, adenosine markedly stimulates
the production of NO in the hypothyroid rats, which is
associated with an increase in glomerular ﬁltration rate;
this eﬀect is completely blocked when L-NAME is coinfused
with adenosine. These results are in agreement with the
results obtained by Quesada et al. [61] who show that nitric
oxide synthase activity remains within the normal range
in the cortex and medulla from hypothyroid rats, which
explains the increased NO results obtained with ADO in the
hypothyroid rats and supports the notion that in hypothy-
roidism the production of NO is regulated by adenosine. In
contrast, Moreno et al. demonstrated, in the isolated kidney
of hypothyroid rats, that the vascular reactivity of the kidney
isreducedtoNOdonors,anditisinsensitivetoNOblockade;
however, renal function was not evaluated in this study [62].
7. Participation of Adenosine in the Regulation
of VascularRelaxation in Hypothyroidism
A limited number of studies have investigated systemic
vascular relaxation under hypothyroid conditions; the evi-
dence available indicates no alterations in response to
acetylcholine (Ach) or CaCl2 in aortic vessels [36, 63];
however, the vasodilation mediated by ADO has not been
completely elucidated. In this regard, it has been suggested
that the aorta has heterogeneous populations of A1 and A2
ADO receptors [64], which inhibit or stimulate adenylate
cyclase, respectively. A3 receptors [65] activate guanylate
cyclase and mediate cellular responses by inducing nitric
oxide production [66]. In this regard, it has been clearly
demonstrated that HTX aortas show a reduced contractile
responsetonoradrenaline(NA)orphenylephrine(PE)when
compared to normal arteries (NL) [67–69], indicating a
lower response to receptor-mediated vasoconstrictors and
nonreceptor-mediated smooth muscle (KCl) in HTX vessels.
Adenosine has been used as a physiological agonist
to investigate the activation of various receptors,
and CPA (N6-cyclopentyladenosine) and NECA (5
 -
ethylcarboxamidoadenosine), the former a speciﬁc agonist
for A1, and for A2a, A2B, and A3 receptors the latter have
been used to investigate the participation of those receptors
in vascular regulation; more speciﬁc A2 (CGS21680) or A3
(IB-MECA) agonists have produced uncertain results in the
NL aorta, suggesting activation of an undeﬁned receptorJournal of Thyroid Research 7
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Figure 4: Response to an adenosine (ADO) blocker (PSPX) in glomerular hemodynamics from normal (NL) and hypothyroid (HTX) rats.
(a) The balance of glomerular blood ﬂow (GBF), the aﬀerent and eﬀerent resistances (AR, ER, resp.), and the permeability of the glomerular
capillarymembrane(Kf)maintainanormalglomerularﬁltrationrate(GFR).(c)Sincenormalglomerularhemodynamicsisnotimportantly
regulated by adenosine, the administration of an adenosine blocker does not modify the GFR. (b) In contrast, renal vasoconstrictions are
observed under hypothyroid conditions. (d) The administration of an adenosine blocker completely reverses the alterations of glomerular
hemodynamics in the hypothyroid kidney. White arrows are indicative of magnitude of AR or ER, whereas yellow arrows represent the
magnitude of the glomerular ﬁltration rate.
[64]. We studied the eﬀect of ADO and ADO agonists, CPA
and NECA, in aortic rings from HTX rats, and they clearly
produced an increase in the maximal relaxation in NA-PE-,
and KCl-contracted rings from the HTX group as compared
with normal vessels (Figure 7).
The A2 ADO receptors are the most abundant in the
normal rat thoracic aorta [70], and they are located in
both endothelium and smooth muscle cells. However, the
predominant action of ADO seems to be mediated by direct
smooth muscle receptor activation [67]; the potency of
responses, NECA>CPA>ADO in NL and HTX aortas, found
in our study was consistent with this report; although the
vasodilator response to ADO has not been explored in
hypothyroidism, our results suggest a higher sensitivity of
the receptors or an increase in number by an upregulation
mechanism [71].
It is generally accepted that vasodilation is endothelium
dependent and is mediated by NO in normal vessels [71].
Some studies have demonstrated that the vasodilator eﬀects
of ADO are mediated by NO production [72]. Certainly, this
is the main mechanism mediating vasodilator responses in
some vessels, such as the guinea pig coronary vasculature
[73], rat mesenteric arteries [74], and renal arteries [75]. In
general, the vasodilator eﬀect of ADO has been considered
partially endothelium dependent [58], but controversial
evidence has been found for the ADO stimulatory eﬀects
on NO production of endothelial cell cultures [73, 76].
As we observed in our experiments, L-NAME did not
signiﬁcantly block the eﬀects of ADO and its analogs in
NA and PE-contracted NL or HTX aortic rings; in contrast,
when the eﬀect of A1 and A2 ADO receptor antagonist
(DPSPX) was evaluated, blocking of ADO receptors with
high concentrations of DPSPX signiﬁcantly reduced the
eﬀects of ADO on HTX vessels but had a small contri-
bution in decreasing the vasodilation in NL vessels. The
vasodilator response in the HTX rings was not completely
inhibited by DPSPX, suggesting the presence of A3 ADO
receptors, since these receptors are resistant to blockade
with several xanthine derivatives, among them DPSPX [77,
78]. The inhibition of relaxation with DPSPX in HTX
aortas greatly supports the hypothesis that ADO receptors
mediate the relaxation response under these conditions. It
has been demonstrated that A2 ADO receptors located in
the endothelial cells induce an age-dependent vasodilatation
response through generation of NO, which stimulates cyclic
GMP in aortic rings [79]. HTX rats may express ADO8 Journal of Thyroid Research
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Figure 5: The adenosine tissue content is markedly aﬀected by hypothyroidism; under normal conditions, the metabolism of adenosine is
very fast, thus the administration of exogenous adenosine within the μmolar range activates preferentially the high-aﬃnity A1 receptors and
induces vasoconstriction (a). In contrast, under hypothyroid conditions, since the metabolism of adenosine is abnormally low, exogenous
adenosine reaches concentrations high enough to activate adenosine A2 receptors and induce vasodilation, (b).
receptors in a similar manner to that of aged rats. Thus, it
is quite possible that ADO receptors located in the smooth
muscle mediate relaxation in the HTX model. The ADO-
mediated vasodilation increase in aortic rings of HTX rats
suggests a novel mechanism in which ADO receptors may be
involved in regulating the vascular tone in hypothyroidism
[67].
In summary, hypothyroidism is characterized by changes
in adenosine receptor number and sensitivity in the kidney,
which results in renal vasoconstriction and induces an
impairment in the ability to concentrate or dilute urine.
Nitric oxide production in the kidney of hypothyroid rats is
mediated by ADO receptors and seems to play an important
role in the regulation of glomerular ﬁltration rate and
renal hemodynamics. In addition, adenosine receptors play
an important role in the regulation of vascular tone in
the hypothyroid rat; however, at least in the aorta, the
eﬀect is directly mediated by ADO receptors with a minor
contribution of NO.
8.HypothyroidismandIntravascular
Metabolism of Lipoproteins
Atherosclerosis is a common feature in hypothyroidism. The
early stages of the atherogenic process are represented in
Figure 8; high-density lipoproteins (HDLs) play a protective
rolebypromotingcholesteroleﬄuxandimprovingendothe-
lial function [80]. Moreover, HDLs have antioxidant [81–
83], antithrombotic [84], and anti-inﬂammatory properties
[85, 86]. HDLs stimulate the synthesis of nitric oxide by the
endothelium [84] and contribute to the endothelial function
through the enzyme paraoxonase-1 (PON1) [81–83]. This
enzyme catalyzes the conversion of the proatherogenic LDL
lipoperoxides to the corresponding lipohydroxides; the for-
mer generated by the reactive oxygen species produce severe
damage to the endothelium, and the latter are biologically
innocuous [72].
In this context, thyroid hormones have been exten-
sively associated with atherosclerosis; overt hypothyroidism
induces high plasma levels of low-density lipoprotein (LDL)
cholesterol, diastolic hypertension, increased coagulability,
and vascular smooth muscle impaired function [87]. There
is substantial epidemiological support for the direct rela-
tionship between hypothyroidism and atherosclerosis. In a
cross-sectional analysis of the Rotterdam study [80], women
with subclinical hypothyroidism had a signiﬁcantly higher
prevalence of aortic atherosclerosis and a higher prevalence
ofmyocardialinfarctionthaneuthyroidwomen,afteradjust-
ment for age, body mass index, high-density lipoprotein
(HDL), blood pressure, and smoking status. Women with
antibodies to thyroid peroxidase in the absence of thyroid
function test abnormalities had a similar prevalence ofJournal of Thyroid Research 9
NL kidney
NL GFR NL UNO2
−/NO3
−
ADO
↓↓ GFR ↑ UNO2
−/NO3
−
(a)
HTX kidney
↓↓↓ GFR NL UNO2
−/NO3
−
ADO
NL GFR ↑↑↑↑ UNO2
−/NO3
−
(b)
Figure 6: The eﬀect of adenosine on urinary excretion of NO2
−/NO3
− (NO2
−/NO3
−). Exogenous adenosine induces a decrease of the
glomerular ﬁltration rate (GFR) in normal (NL) kidneys and slightly increases the urinary excretions of nitrites. In contrast, in the
hypothyroid (HTX) kidneys, despite the vasoconstriction, the urinary excretion of nitrates is within the normal range. When exogenous
adenosine is administrated to HTX kidney, the glomerular ﬁltration rate returns to normal values but is associated with a marked increase
in the UNO2
−/NO3
−, suggesting that this eﬀect is mediated by nitric oxide.
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Figure 7: In spite of a similar norepinephrine-induced vasoconstriction of the aortic rings from normal (NL) and hypothyroid (HTX) rats,
adenosine- (ADO-) induced vasodilation is markedly higher in the HTX aortic rings. Increased number of adenosine receptors or a higher
sensitivity to the receptors to exogenous adenosine may explain the higher sensitivity of HTX aortic rings to ADO.
aortic atherosclerosis and myocardial infarction as euthyroid
women without antibodies, suggesting that the increased
atherosclerosis was mediated by relative T4 deﬁciency rather
than immune dysfunction.
In agreement with this notion, the Whickham Survey
revealed an association between incident ischemic heart dis-
ease (IHD) events and IHD-related mortality with subclini-
cal hypothyroidism over a 20-year followup [88, 89]. How-
ever, subsequent treatment of subclinical hypothyroidism
with levothyroxine attenuated IHD-related morbidity and
mortality, supporting the concept that T4 plays a direct
role on the protection against coronary events. Besides,
in a recent meta-analysis, it was suggested that subclinical
hypothyroidism is associated with an increased risk of
congestive heart failure among older adults with a TSH level
of 7.0mIU/L or greater, but not with coronary heart disease,
stroke, peripheral arterial disease, or cardiovascular-related
mortality [90].
The molecular basis of the protective role of thyroid
hormones against atherosclerosis is mainly related with10 Journal of Thyroid Research
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Figure 8: Early stages of the atherogenic process. (1) Low-density lipoproteins (LDLs) reach the subendothelial space. (2) LDLs become
oxidized by reactive oxygen species (ROS). (3) Oxidized LDLs act as chemotactic molecules for monocytes. (4) Monocytes diﬀerentiate in
macrophages within the subendothelial space (5) Macrophages further phagocyte oxidized LDL with the consequent lipid accumulation
in their cytoplasm, originating a foam cell that favours an inﬂammatory response by stimulating the endothelial expression of adhesion
molecules.
the regulation of the intravascular metabolism of lipopro-
teins. Elevated levels of total cholesterol, LDL-cholesterol,
and apo B are well-documented features of hypothy-
roidism [91]. The metabolic origin of such abnormalities
has been described in previous studies; propylthiouracil-
induced hypothyroidism in rats resulted in nearly 50%
decrease of LDL receptor mRNA levels in the liver. In
agreement with these observations, LDL receptor mRNA
levels increase more than 50% in euthyroid rats supple-
mented with T4 [92]. Therefore, decreased LDL receptor
expression explains the low LDL clearance observed in
cultured human skin ﬁbroblasts [93]. Low LDL clearance
was also observed in early studies using isotopically labeled
lipoproteins in humans [94] and reviewed elsewhere [87].
These ﬁndings were supported by an “in vivo”s t u d y
in a hypothyroid woman whose receptor-mediated LDL
catabolism was reduced, compared with euthyroid controls,
with signiﬁcant improvement after T4 replacement therapy
[95].
Further studies have established the molecular mecha-
nismsthatexplaintheregulationofLDLreceptorsbythyroid
hormones; the promoter region of the gene coding for
LDL receptor contains functional thyroid response elements.
When the LDL receptor promoter was linked to a reporter
gene and cotransfected with the β1 isoform of the thyroid
hormone receptor into a hepatic cell line, activity of the
chimeric gene was observed when it was stimulated with T3
[96]. The speciﬁcity of diﬀerent thyroid hormone receptors
has been recently considered for drugs design, and they are
discussed below.
Thyroid hormones also contribute to regulate the intra-
vascular metabolism of high-density lipoproteins (HDLs)
(Figure 9). HDLs, as other lipoproteins, are complex macro-
moleculescomposedofphospholipidsandfreecholesterolon
the surface and cholesteryl esters and triglycerides nonpolar
lipids in the core. The physicochemical stability of HDL is
guaranteed by several apolipoproteins; apo AI represents up
to 70% of the protein mass whereas apo AII is the second
more abundant protein of HDL. HDLs are secreted as
discoid particles containing lipid-poor apo AI, and then they
rapidly acquire phospholipids and unesteriﬁed cholesterol
from tissues via the ABC-A1 transporter to become spherical
HDL particles (Figure 9). HDLs facilitate a process known
as reverse cholesterol transport (RCT) in which cholesterol
in peripheral tissues is delivered to these lipoproteins and
ultimately returned to the liver for excretion in bile and
feces.
The important role of HDL in the antiatherosclerotic
process [81–86, 97] highlights the function of thyroid
hormones on the intravascular metabolism of these lipopro-
teins. Clinical studies have reported conﬂicting results about
HDL-cholesterol plasma levels in hypothyroidism; signiﬁ-
cantly lower HDL-cholesterol plasma concentrations were
described when 52 patients with subclinical hypothyroidism
and 18 with overt hypothyroidism were compared with 46
euthyroid controls [98]. Caron et al. [99] also reported
that the HDL cholesterol level was signiﬁcantly decreased
among 29 women who had subclinical hypothyroidism,
compared with 41 euthyroid women matched for age and
metabolic parameters. Furthermore, a signiﬁcant increase in
HDL cholesterol plasma levels wasobserved after T4 therapy,
which normalized the serum TSH concentration [99]. In
contrast,otherreportsconcludethatHDLcholesterolplasma
levels are normal or even increased in human hypothy-
roidism [100–102] with a signiﬁcant decrease after T4
treatment[103].TheeﬀectofT4onHDL-Cinthisstudywas
independent from LDL receptor and CETP polymorphisms
[103]. In addition, a controlled trial in which 66 women withJournal of Thyroid Research 11
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Figure 9: Intravascular metabolism of lipoproteins. (a) Very low-density lipoproteins (VLDLs) synthesized by the liver follow a lipolstic
cascadeuptotheformationoflow-densitylipoproteins(LDLs),whichareclearedfromplasmabytheapoB/apoEhepaticreceptor(apoB/E-
R). The cholesteryl esters transfer protein (CETP) facilitates the exchange of triglycerides from apo B containing lipoproteins to HDL and
cholesteryl esters in the opposite sense. (b) High-density lipoproteins (HDL) pick up cholesterol from peripheral tissues, including the foam
cells. HDL cholesterol becomes esteriﬁed by the activity of the lecithin:cholesterol acyl transferase (LCAT). Cholesteryl esters are cleared
from plasma by the hepatic scavenger receptor class B, type I (SR-BI) or via CETP. Proteins involved in lipid metabolism that are regulated
by thyroid hormones have been highlighted with green circles; low expression levels of SR-BI have not been reported (indicated by a green
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subclinical hypothyroidism were randomly assigned to T4 or
placebotreatmentfoundnosigniﬁcantchangeineitherHDL
cholesterol or apolipoprotein AI [104].
Hence, there is not a constant pattern concerning HDL-
cholesterol in hypothyroidism. Interestingly, several proteins
related with HDL metabolism are aﬀected by thyroid
hormones (Figure 9(b)). Cholesteryl ester transfer protein
(CETP)activityhasbeenreportedinhumanhypothyroidism
[92,93];lowCETPactivityinducescholesterolaccumulation
in HDL particles that result in high HDL-C plasma levels
[97]. In contrast, thyroidectomized rats, an animal species
that lacks CETP activity, were characterized by a signiﬁcant
decrease of HDL-cholesterol and apo AI of about 26%
and 23%, respectively, as compared to controls. These
paradoxicalresultssuggestthatthevariabilityofHDLcholes-
terol among hypothyroid patients is not related to CETP
activity.
Another key enzyme in intravascular HDL metabolism is
LCAT (Figure 9(b)); the activity of this enzyme was found to
be lower in hypothyroid rats than in controls [105], probably
due to a decreased secretion of the protein by the hepatocyte
[106]. It could be suggested that low LCAT activities are
consistentwithincreasedlevelsofHDLcholesterol,sincefree
c h o l e s t e r o li su n a b l et oc o n t i n u ei t sc l e a r a n c ef r o mp l a s m a .
However, thyroidectomized rats exhibit low HDL cholesterol
plasma levels as mentioned above, associated to low LCAT
activities, suggesting a minimal contribution of this enzyme
to abnormal HDL concentrations [106].
Low hepatic lipase (HL) seems to be another feature
of hypothyroidism [105, 107]. HL catalyzes the hydrolysis
of HDL triglycerides with the consequent remodeling of
these lipoproteins towards smaller particles (Figure 9(b)). In
agreement with this idea, HDL isolated from hypothyroid
rats was signiﬁcantly larger than those from euthyroid rats
[108]. Since large HDLs are the best ligands of hepatic scav-
engerreceptorB,classI(SR-BI),cholesterylestersarecleared
faster from plasma; the consequence of such enhanced
interaction would be decreased HDL cholesterol plasma
levels, as has been observed in hypothyroid rats [105, 108].
Another protein that regulates the metabolism of HDL
and whose expression is likely controlled by thyroid hor-
mones is the hepatic SR-BI [109]. SR-BI promotes the
selective uptake of cholesteryl esters contained in HDL,
particularly from the largest subclasses of these lipoproteins
[110]. Studies with mice treated with GC-1, an analog of
thyroid hormones with high aﬃnity for the thyroid receptor
beta induced an overexpression of SR-BI [109]w h i c h
suggests that in hypothyroidism the synthesis of this protein
is decreased. To our knowledge, low levels of SR-BI hepatic
expression have not been described yet. However, Huesca-
G´ omez et al. described large HDL isolated from plasma of
thyroidectomized rats [108]. This feature is consistent with a
low expression of hepatic SR-BI since HDL become smaller
after interacting with the receptor [110].
Reduced paraoxonase-1 activity paraoxonase-1 (PON1)
activities is another important consequence probably related
to the abnormal HDL structure in hypothyroidism [108].
PON1 is an enzyme that plays an important role against the
toxicity of organophosphosphate pesticides [111], but it also
catalyzes the conversion of lipoperoxides characteristic of
the ﬁrst stages of atherome formation to the corresponding
lipohydroxides that are biologically innocuous [112]. In
this context, PON1 has been considered as an antioxidant
and antiatherogenic enzyme. PON1 is physically associated
to HDL by hydrophobic interactions, the smallest HDL
particles being the best carriers [83, 113]. Since HDL size is
increased during the hypothyroid status, low plasma levels
of PON1 could be expected. Indeed, low PON1 plasma
activities have been consistently reported in hypothyroid
patients [114, 115] with signiﬁcant increases after thyroxine
replacement [115].
Low levels of thyroid hormones are also associated
with an important decrease of apo AI catabolic rates of
about 40%, as demonstrated in thyroidectomized rats [108].
Such a low apo AI clearance was associated to very low
synthesis rates of the protein, almost 60% lower than those
of controls. The ﬁnal balance of this metabolic behavior
was a low plasma level of apo AI in hypothyroid rats [108].
This study clearly showed that hypothyroidism aﬀects both
synthesis and catabolism of the major component of HDL.
Genetic and environmental factors may inﬂuence the ﬁnal
balance between the reduced synthesis and catabolism of
HDL-apo AI in hypothyroid subjects; consequently, HDL
plasma levels may be low, unchanged, and even increased,
in function of the environmental and genetic background of
each individual.
Aggressive reduction of LDL cholesterol is the basis of
preventive cardiovascular care [116], but additional thera-
peutic approaches to reduce atherogenesis are still needed.
Sincethyroidhormoneshaveavastconstellationofbeneﬁcial
eﬀects on lipoprotein metabolism, T4 analogs were consid-
ered to treat hypercholesterolemia. The apparent deleterious
eﬀects on heart function as well as the introduction of
statins led to the discontinuation of clinical studies with T4
analogsin the 1970s. However, thyromimetic drugsare being
explored to treat dyslipidemias (for a review, see [117]). Of
particular interest have been the thyromimetics with high
aﬃnity for the thyroid receptor (TR) beta-1 which is the
predominant isoform of the hepatocyte that is almost absent
in the heart [117, 118]. In consequence, TR-beta-1 agonists
would improve lipoprotein metabolism without the negative
impactontheheart[119].Thepreliminaryresultswithsome
thyromimetics are promising, and the ﬁnal outcomes will
deﬁne whether or not these drugs will become an alternative
for statins.
In summary, high plasma levels of LDL cholesterol
are a common feature of hypothyroidism. The metabolic
basis of this abnormality is a low expression of the hepatic
LDL receptor, since the gene coding for this protein is
positively regulated by T4. Concerning the HDL, the proﬁle
is uncertain in hypothyroid subjects; proteins related to HDL
metabolism such as HL, LCAT, possibly SR-BI, and the main
constituent of HDL, apo AI, are expressed at lower levels
under hypothyroid conditions. Consequently, the HDL
metabolism is greatly aﬀected in hypothyroidism, but the
impact of such metabolic impairment on HDL cholesterol
plasma levels is variable. On the basis of the positiveJournal of Thyroid Research 13
inﬂuence of thyroid hormones on lipoprotein metabolism,
thyromimetic drugs with speciﬁcity for TR-beta-1 are very
promising for the treatment of dyslipidemia.
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